Clinical trial
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
NCT00448292
Study timeline
Study start (unknown)2007-03-01Date precision: month
Registry last updated2007-11-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Major Depressive Disorder (MDD)unresolved
Interventions
PRX-00023DRUG
Sponsors & collaborators
Epix Pharmaceuticals, Inc.lead sponsor
Mapped research locations
ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1AtlantaGeorgia, United States1SeattleWashington, United States1Washington D.C.District of Columbia, United States1JacksonvilleFlorida, United States1CharlestonSouth Carolina, United States1CharlotteNorth Carolina, United States1TorranceCalifornia, United States1ShreveportLouisiana, United States1Overland ParkKansas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00448292 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.